T3D Therapeutics’ mission is to develop its lead drug product candidate, T3D-959, as a potential ‘First-in-Class’ and ‘Best-in-Class’ disease-modifying, breakthrough medicine for the treatment of Alzheimer’s disease with the potential to slow, stop or reverse the course of the disease.

Pharmaceutical

T3D Therapeutics

John Didsbury

David Keim

Jessica Stanek

Hoda Gabriel

Blake Swearingen

Stan Chamberlain

Warren Strittmatter

The Advisory and Consulting team at T3D Therapeutics provides expert guidance and strategic advice on the development and clinical testing of T3D-959. Leveraging their extensive industry knowledge, they support the company in regulatory affairs, market positioning, and optimizing treatment protocols to advance T3D-959 as a leading therapy for Alzheimer's disease.

Advisory and Consulting

Leadership Team

Advisory and Consulting

About

Team members

Other teams at T3D Therapeutics

Leadership Team